Zanubrutinib
Engraftment Syndrome
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Engraftment Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Monomethyl Fumarate National Cancer Institute (NCI) | Phase 2 | B |
PENTOSTATIN National Cancer Institute (NCI) | Phase 2 | B |
cc-5013 National Cancer Institute (NCI) | Phase 2 | B |
Obinutuzumab National Cancer Institute (NCI) | Phase 2 | B |
FILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
CYCLOSPORIN A National Cancer Institute (NCI) | Phase 2 | B |
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | B |
Rapamycin National Cancer Institute (NCI) | Phase 2 | B |
Same molecule, other indications
Zanubrutinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →